“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 27, 2025

Adolor Corporation


Adolor Corporation — A to Z Product Catalog

Marketed Product

  • ENTEREG® (alvimopan)
    • Generic: Alvimopan (peripherally-acting mu-opioid receptor antagonist)
    • Indication: Accelerates upper and lower gastrointestinal recovery (POI) following partial large or small bowel resection with primary anastomosis
    • Dose/Form: Oral, short-term use in hospitals enrolled in a restricted-access program

Investigational or Historical Candidates

  • ADL5859
    • Type: Delta-opioid receptor agonist
    • Indication (studied): Inflammatory, neuropathic, and acute pain (e.g., rheumatoid arthritis, dental surgery, diabetic neuropathy)
    • Dose/Form: Orally administered; Phase 2a trial dosing per protocol

  • ADL5747
    • Type: Delta-opioid receptor agonist
    • Indication (studied): Pain relief (phase 1 trial)
    • Dose/Form: Oral; Phase 1 dosing per protocol

  • ADL5945
    • Type: Peripherally-acting mu-opioid receptor antagonist
    • Indication (studied): Chronic opioid-induced constipation (OIC)
    • Dose/Form: Phase 2 study of 0.10 mg and 0.25 mg twice daily; also studied at 0.25 mg once daily

  • ADL7445
    • Type: Peripherally-acting mu-opioid receptor antagonist (backup compound for OIC)
    • Indication (studied): Opioid-induced bowel dysfunction (OIC)
    • Dose/Form: Preclinical / IND preparation; dosing not finalized

  • ADL6906 (Beloxepin)
    • Type: Investigational compound (mechanism unspecified)
    • Indication (studied): Evaluated in Phase 1 trials
    • Dose/Form: Phase 1 dosing

  • ADL10-0101
    • Type: Peripheral kappa-opioid receptor agonist
    • Indication (studied): Pain (visceral pain, inflammatory conditions)
    • Dose/Form: Early trials; dosing per Phase 1/Phase 2 design

  • ADL10-0116
    • Type: Peripheral kappa-opioid receptor agonist
    • Indication (studied): Inflammatory pain conditions
    • Dose/Form: Early clinical; dosing per Phase 1 design

  • ADL2-1294 (Loperamide-like)
    • Type: Peripheral mu-opioid receptor agonist (e.g. loperamide analog)
    • Indication (studied): Pain (dermal/intra-articular), itch; ophthalmic pain studied previously
    • Dose/Form: Preclinical / early-stage; dosing per development


on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)